October 2025 proved to be a significant month for the oncology landscape, marked by a wave of key regulatory decisions from the US FDA. This period saw important full and accelerated drug approvals ...
Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.